Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q4 2022 call → NO我们根据指令,需要判断管理层是否描述了“连续同类业务以逐渐更大的规模到来”的现象。即,公司现在签下的交易、订单、合同、项目、客户、站点或项目是否比之前更大、更广或更长。 在通话记录中,管理层提到了几个方面: - 客户增长:新增约23,000个净新地点,但这是数量增长,不是单个规模。 - 产品采用:41%的客户附加6个以上SaaS模块,比去年32%增加,但这是渗透率,不是单个客户规模。 - 提到了一些客户案例,如Cameron Mitchell restaurants、Michael's Harborside、Teaspoon等,但这些都是具体客户,没有明确说这些客户比以前的客户更大或更广。 - 关于QSR和Delphi收购,但那是产品扩展,不是交易规模。 - 关于ARPU:SaaS ARPU同比增长20%,但这是平均每个地点的收入,不是单个合同规模。 - 管理层没有明确说“新签的合同比过去更大”或“每个新客户现在带来更多收入”之类的表述。 在问答环节,有分析师问“front book ARPU”是否在6000左右,Elena说“we're definitely in that zone”,但这是确认,没有说比过去更大。 因此,没有证据表明管理层描述了“同类业务规模递增”的现象。他们谈论的是增长、数量、ARPU提升,但ARPU提升可能来自产品附加,而不是单个合同规模扩大。没有明确比较现在与过去的单个交易规模。 所以答案应为NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.